Press "Enter" to skip to content

New Molecule Prevents Heart Cells From Heart Attack Injuries

A team of researchers has designed a novel molecule that could prevent the occurrence of major injuries to heart cells during, and even after a cardiovascular attack. The scientists described the development and effectiveness of the molecule in the research paper published in the Journal of the American Heart Association.

In general, heart cells lose viability at a faster rate due to insufficient blood and oxygen supply. In case of a heart attack, less oxygen and blood supply generates hypoxic-ischemic injury into a specific section of a heart, which induces those injured cells to transmit signals to their neighboring cells. In scientific terms, this transmission of injury signals to nearby healthy cells is known as “bystander effect.”

The researchers thought of restricting the signal transmission by the injured heart cells keeping the nearby healthy muscle cells remain intact. Almost a decade back, Robert Gourdie— director of the Fralin Biomedical Research Institute—along with his team discovered a compound, known as alphaCT1, which is responsible for regulating the bystander effect.

The researchers designed the molecules by slightly altering the parent compound. They revealed that alphaCT11; variant of alphaCT1, alleviate the effect of robust ischemic injury.

On a related note, in order to prevent the higher risk of occurrence of cardiovascular diseases, the main objective is to reduce the LDL cholesterol (LDL-C). Patients, who had been suffering from ACS or CHD, are strongly prescribed to take cholesterol-lowering drugs. At present, statins are the most prevalent group of drugs, which are recommended for lowering of cholesterol levels.

A researchers’ team at the Institute for Quality and Efficiency in Healthcare (IOWiG) in Germany, indicated that a combination of ezetimibe and statin is more beneficial rather than a statin alone. Cardiologists have been recommending the patients with a higher risk of heart attack to intake statin together with ezetimibe for further reduction of LDL cholesterol.

Brent Schmidt
Brent Schmidt Subscriber
Managing Editor At Daily Market Journal

Brent accomplished Doctor of Medicine Degree and started his career in the Health domain as a successful practitioner. However, his interest in connecting and educating people while continuing his present work motivated him to write articles on the Daily Market Journal news platform. He is a key member in our team of expert writers with a strong experience of 6 years in the Health sector. Despite his busy schedule, Brent spares time to write blogs for Daily Market Journal’s Health section on a regular basis. Although he holds a strong background of education and experience, Brent is a soft-spoken person and acclaimed as a great storyteller.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *